Claims
- 1. A substituted aminomethylchroman of the formula ##STR171## in which Y denotes a straight-chain or branched, saturated or unsaturated alkylene chain having up to 6 carbon atoms,
- Z denotes a group of the formula ##STR172## w denotes 0, 1 or 2, p denotes 1 or 2,
- R.sup.1 denotes hydrogen, lower alkyl or benzyl or
- denotes the group --(Y.sup.1 -Z.sup.1), where Y.sup.1 or Z.sup.1 may be identical or different to Y and Z have the abovementioned meaning of Y and Z,
- E and F are identical or different and
- denote hydrogen, lower alkyl or lower alkoxy or
- denote fluorine, chlorine, bromine, cyano or
- denote a group of the formula --CONH.sub.2, or
- E and F together form a phenyl or cyclohexane ring, or a salt thereof.
- 2. A compound according to claim 1, wherein such compound is the (+) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl) chroman of the formula ##STR173## or a salt thereof.
- 3. A compound according to claim 1, wherein such compound is the (-) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl}chroman of the formula ##STR174## or a salt thereof.
- 4. A compound according to claim 1, wherein such compound is the (+) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl}-8-methoxy chroman of the formula ##STR175## or a salt thereof.
- 5. A compound according to claim 1, wherein such compound is the (-) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl}-8-methoxy chroman of the formula ##STR176## or a salt thereof.
- 6. A 5-HT.sub.1 receptor-binding composition comprising a 5-HT.sub.1 receptor-binding amount of a compound; or salt according to claim 1 and a diluent.
- 7. A unit dose of a composition according to claim 1 in the form of a tablet, capsule or ampoule.
- 8. A method of binding the 5-HT.sub.1 receptors of a patient in need thereof which comprises administering to a patient in need thereof an amount effective therefor of a compound or salt according to claim 1.
- 9. The method according to claim 8, wherein such compound is
- (+) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl}chroman,
- (-) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl}chroman,
- (+) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl}-8-methoxy chroman,
- (-) enantiomer of 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-butyl]aminomethyl}-8-methoxy chroman,
- 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)butyl]aminomethyl}-8-methoxy-chroman,
- 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)butyl]aminomethyl}-5-methoxy-chroman, or
- 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)butyl]aminomethyl}-benzo(h)chroman,
- or a salt thereof.
- 10. A compound according to claim 1, wherein such compound is 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)butyl]aminomethyl}-8-methoxy-chroman of the formula ##STR177## or a salt thereof.
- 11. A compound according to claim 1, wherein such compound is 2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl-butyl]aminomethyl}-5-methoxy-chroman of the formula ##STR178## or a salt thereof.
- 12. A compound according to claim 1, wherein such compound is 2-{N-[4(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)butyl]aminomethyl}benzo(h)chroman of the formula ##STR179## or a salt thereof.
- 13. A compound according to claim 1, wherein such compound is 2-{N-[4-(2,3-dihydrobenzisothiazol-2-yl)butyl]}amino-methyl-8-methoxy-chroman of the formula ##STR180## or a salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
3825609 |
Jul 1988 |
DEX |
|
3901814 |
Jan 1989 |
DEX |
|
Parent Case Info
This is a continuation-in-part of Application Ser. No. 07/378,732, filed Jul. 12, 1989, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4748182 |
Hibert et al. |
May 1988 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0236930 |
Sep 1987 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
378732 |
Jul 1989 |
|